PL3242884T3 - Kationowe neurotoksyny - Google Patents

Kationowe neurotoksyny

Info

Publication number
PL3242884T3
PL3242884T3 PL15701379T PL15701379T PL3242884T3 PL 3242884 T3 PL3242884 T3 PL 3242884T3 PL 15701379 T PL15701379 T PL 15701379T PL 15701379 T PL15701379 T PL 15701379T PL 3242884 T3 PL3242884 T3 PL 3242884T3
Authority
PL
Poland
Prior art keywords
neurotoxins
cationic
cationic neurotoxins
Prior art date
Application number
PL15701379T
Other languages
English (en)
Polish (pl)
Inventor
Dina Brady ANDERSON
Gavin Stephen HACKETT
Sai Man LIU
Original Assignee
Ipsen Bioinnovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Limited filed Critical Ipsen Bioinnovation Limited
Publication of PL3242884T3 publication Critical patent/PL3242884T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL15701379T 2015-01-09 2015-01-09 Kationowe neurotoksyny PL3242884T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2015/050043 WO2016110662A1 (en) 2015-01-09 2015-01-09 Cationic neurotoxins
EP15701379.8A EP3242884B1 (en) 2015-01-09 2015-01-09 Cationic neurotoxins

Publications (1)

Publication Number Publication Date
PL3242884T3 true PL3242884T3 (pl) 2021-08-16

Family

ID=52424029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15701379T PL3242884T3 (pl) 2015-01-09 2015-01-09 Kationowe neurotoksyny

Country Status (12)

Country Link
US (3) US10647750B2 (enExample)
EP (2) EP3822286A1 (enExample)
JP (1) JP6601922B2 (enExample)
CN (2) CN116333068A (enExample)
DK (1) DK3242884T3 (enExample)
ES (1) ES2873479T3 (enExample)
HU (1) HUE053935T2 (enExample)
PL (1) PL3242884T3 (enExample)
PT (1) PT3242884T (enExample)
RU (1) RU2733493C2 (enExample)
TW (1) TWI700289B (enExample)
WO (1) WO2016110662A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
PL3481852T3 (pl) * 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne
TW201814045A (zh) * 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
RU2766147C2 (ru) * 2017-03-22 2022-02-08 Бонти, Инк. Применение ботулинических нейротоксинов в лечении
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
BR112021016324A2 (pt) * 2019-02-20 2021-11-16 Regresar Medical Inc Métodos e dispositivos para localizar composições
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
CA3211472A1 (en) 2021-03-30 2022-10-06 Mikhail KALINICHEV Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
BR112023020057A2 (pt) 2021-03-30 2024-03-12 Ipsen Biopharm Ltd Tratamento de dor e distúrbios inflamatórios
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
EP1099445A3 (en) 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
WO2000067700A2 (en) * 1999-05-12 2000-11-16 United States Army Medical Research & Materiel Cmd Recombinant vaccine against botulinum neurotoxin
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5714469A (en) 1994-09-01 1998-02-03 Smithkline Beecham Corporation Method of treating sepsis
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU4746096A (en) * 1995-06-06 1996-12-24 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin
AU6326896A (en) * 1996-03-08 1997-09-22 Regents Of The University Of California, The Chemically-modified clostridiatoxin with improved properties
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
AU755513B2 (en) 1998-05-13 2002-12-12 Merz Pharma Gmbh & Co. Kgaa Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
JP4454152B2 (ja) 1998-07-22 2010-04-21 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 二次的組織損傷ならびにその他の炎症症状および疾患を治療する方法および組成物
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
CA2380457A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
AU2003287155A1 (en) 2002-10-15 2004-05-04 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US7172764B2 (en) 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
EP1773874B1 (en) * 2004-08-04 2012-10-24 Allergan, Inc. Optimizing expression of active botulinum toxin type a
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
CA2595115C (en) 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
BRPI0608249A2 (pt) * 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
JP5167473B2 (ja) * 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK1926744T4 (en) 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
EP2038299A2 (en) * 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
AU2007347781B2 (en) 2006-07-11 2013-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
AU2010236613B2 (en) 2009-04-14 2016-07-07 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
AU2010267963B2 (en) 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
CA2788074C (en) * 2010-01-25 2016-07-12 Allergan, Inc. Methods of intracellular conversion of single-chain proteins into their di-chain form
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
CA2855173A1 (en) * 2011-11-09 2013-05-16 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
US9315549B2 (en) * 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins

Also Published As

Publication number Publication date
TWI700289B (zh) 2020-08-01
JP6601922B2 (ja) 2019-11-06
DK3242884T3 (da) 2021-04-19
PT3242884T (pt) 2021-04-22
HUE053935T2 (hu) 2021-08-30
RU2017128211A (ru) 2019-02-11
HK1245292A1 (en) 2018-08-24
RU2017128211A3 (enExample) 2019-02-11
WO2016110662A1 (en) 2016-07-14
CN116333068A (zh) 2023-06-27
ES2873479T3 (es) 2021-11-03
US10647750B2 (en) 2020-05-12
EP3242884A1 (en) 2017-11-15
US20180141982A1 (en) 2018-05-24
US11014968B2 (en) 2021-05-25
EP3242884B1 (en) 2021-02-24
EP3822286A1 (en) 2021-05-19
US20210246175A1 (en) 2021-08-12
TW201629092A (zh) 2016-08-16
US20200291073A1 (en) 2020-09-17
JP2018502580A (ja) 2018-02-01
US12037369B2 (en) 2024-07-16
RU2733493C2 (ru) 2020-10-02
CN107108703B (zh) 2022-09-23
CN107108703A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
PT3242884T (pt) Neurotoxinas catiónicas
DK3389557T3 (en) Transseptalt leveringssystem
DK3320033T3 (en) Polyethylenterephthalat-depolymerisering
DK3256579T3 (en) Cysteinprotease
DK3250592T3 (en) Anti-transthyretin-antistoffer
GB201621111D0 (en) Neurotoxins
DK3373882T3 (en) Patientisolator
DK3284069T3 (en) Pos-terminal
DK3380145T3 (en) Injektionsapparat
DK3336185T3 (en) Antistof
DK3272750T3 (en) Morphinan-derivat
IL256253A (en) Variants of il-37
DK3324768T3 (en) Tørdragt
GB2541867B (en) Polytunnel arrangement
GB2545956B (en) Vibro-polishing arrangement
DK3282866T3 (en) Proteinfibre
DK3250312T3 (en) Urea-metalnitrat-scr-system
GB2540412B (en) Polytunnel arrangement
DK3294653T3 (en) Justerbar inline-port
GB2544388B (en) Polytunnel Arrangement
AU5516P (en) LEP08 Lepidosperma squamatum
AU5511P (en) PTK647 Epichloe coenophiala
GB201516350D0 (en) Anywhere bankstick
AU366552S (en) Nutblock
AU367131S (en) USB-charger